Skip to main content

MacroGenics, Inc. (MGNX)

NASDAQ: MGNX · Delayed Price · USD
20.50
+0.76 (3.85%)
After-hours:Sep 24, 2021 7:30 PM EDT
19.74
-0.80 (-3.89%)
At close: Sep 24, 4:00 PM
Market Cap1.21B
Revenue (ttm)118.58M
Net Income (ttm)-129.34M
Shares Out60.07M
EPS (ttm)-2.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume345,147
Open20.51
Previous Close20.54
Day's Range19.72 - 20.87
52-Week Range18.16 - 36.48
Beta2.20
AnalystsBuy
Price Target36.25 (+83.6%)
Est. Earnings DateNov 4, 2021

About MGNX

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, w...

IndustryBiotechnology
IPO DateOct 10, 2013
CEOScott Koenig
Employees370
Stock ExchangeNASDAQ
Ticker SymbolMGNX
Full Company Profile

Financial Performance

In 2020, MacroGenics's revenue was $104.88 million, an increase of 63.40% compared to the previous year's $64.19 million. Losses were -$129.74 million, -14.54% less than in 2019.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MacroGenics stock is "Buy." The 12-month stock price forecast is 36.25, which is an increase of 83.64% from the latest price.

Price Target
$36.25
(83.64% upside)
Analyst Consensus: Buy

News

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society f...

1 week ago - Benzinga

Why MacroGenics Stock Is Tanking Today

Investors weren't thrilled with the company's latest clinical data.

1 week ago - The Motley Fool

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presente...

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

1 week ago - GlobeNewsWire

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combinatio...

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

1 week ago - GlobeNewsWire

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

2 weeks ago - GlobeNewsWire

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...

2 weeks ago - Zacks Investment Research

Why MacroGenics Soared Nearly 9% Higher Today

Investors are signaling hope in the company's top drug, despite a disappointing final analysis.

2 weeks ago - The Motley Fool

MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast cancer med Herceptin.  But Margenza's over...

2 weeks ago - Benzinga

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Me...

ROCKVILLE, MD, Sept. 07, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

2 weeks ago - GlobeNewsWire

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

3 weeks ago - GlobeNewsWire

Why MacroGenics Stock Is Tumbling Today

The company provided its Q2 update.

1 month ago - The Motley Fool

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

1 month ago - GlobeNewsWire

MacroGenics (MGNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti...

2 months ago - GlobeNewsWire

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Other symbols:BEAMBOLTGMABZLAB
2 months ago - PennyStocks

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to c...

3 months ago - PRNewsWire

MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal

MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules. The first collaborati...

Other symbols:ZLAB
3 months ago - Benzinga

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific ...

ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) --   MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-ant...

3 months ago - GlobeNewsWire

Why MacroGenics Stock Is Tumbling Today

The company announced preliminary phase 1 results for its tumor-fighting drug MGC018.

4 months ago - The Motley Fool

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics ...

4 months ago - GlobeNewsWire

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

4 months ago - GlobeNewsWire

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

ROCKVILLE, Md., April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti...

4 months ago - GlobeNewsWire

Will MacroGenics (MGNX) Report Negative Earnings Next Week? What You Should Know

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research